专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009031834A2 HYBRIDIZATION METHOD BETWEEN LEUCINE RICH REPEAT FAMILY PROTEINS 审中-公开
标题翻译：荔枝富集重复家系蛋白的杂交方法
公开(公告)号：WO2009031834A2
公开(公告)日：2009-03-12
申请号：PCT/KR2008/005220
申请日：2008-09-04
申请人： KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY , LEE, Jie-Oh , KIM, Ho-Min , PARK, Beom Seok , JIN, Mi Sun , YOO, Ook Jun
发明人： LEE, Jie-Oh , KIM, Ho-Min , PARK, Beom Seok , JIN, Mi Sun , YOO, Ook Jun
IPC分类号： C07K19/00 , C12P19/34
CPC分类号： C12N15/62 , C07K14/705
摘要： Disclosed is a method for fusing proteins. More specifically, disclosed is a method of fusion between LRR (Leucine Rich Repeat )-famiIy proteins, the method comprising fusing the LRR-family proteins with each other at the following consensus sequence position: LxxLxxLxLxxN, wherein L represents alanine, glycine, phenylalanine, tyrosine, isoleucine, valine or tryptophane, N represents asparagine, glutamine, serine, cysteine or threonine, and X represents any amino acid. According to the disclosed fusion LRR technique, a fusion protein having high crystallinity can be obtained by fusing an LRR-family protein having high crystallinity with another LRR-family protein having low crystallinity. Thus, the fusion LRR technique is useful to determine the structures of proteins having low crystallinity. Furthermore, because the active regions and mechanisms of proteins can be understood from the structural analysis of the proteins, the fusion LRR technique can be effectively to understand the in vivo action of the proteins and develop therapeutic drugs. In addition, according to the fusion LRR technique of the present invention, fusion proteins, which have high crystallinity while maintaining the function of the respective proteins, can be produced in large amounts. Thus, the fusion LRR technique is useful for the development of protein drugs.
摘要翻译：公开了用于融合蛋白质的方法。更具体地，公开了LRR（富含亮氨酸重复序列） - 蛋白质之间融合的方法，所述方法包括在下列共有序列位置处将LRR家族蛋白彼此融合：LxxLxxLxLxxN，其中L代表丙氨酸，甘氨酸，苯丙氨酸，酪氨酸，异亮氨酸，缬氨酸或色氨酸，N代表天冬酰胺，谷氨酰胺，丝氨酸，半胱氨酸或苏氨酸，并且X代表任何氨基酸。根据公开的融合LRR技术，可以通过将具有高结晶度的LRR家族蛋白与具有低结晶度的另一种LRR家族蛋白融合来获得具有高结晶度的融合蛋白。因此，融合LRR技术可用于确定具有低结晶度的蛋白质的结构。此外，因为可以从蛋白质的结构分析中理解蛋白质的活性区域和机制，所以融合LRR技术可以有效地理解蛋白质的体内作用并开发治疗药物。另外，根据本发明的融合LRR技术，可以大量生产具有高结晶度同时保持各个蛋白质的功能的融合蛋白。因此，融合LRR技术对于蛋白质药物的开发是有用的。

2. 发明申请

WO2009090493A3 TLR4 DECOY RECEPTOR PROTEIN 审中-公开
标题翻译： TLR4诱饵受体蛋白
公开(公告)号：WO2009090493A3
公开(公告)日：2009-11-26
申请号：PCT/IB2008003936
申请日：2008-12-08
申请人： KOREA ADVANCED INST SCI & TECH , JUNG KEEHOON , KIM HOMIN , KIM HAK-ZOO , LEE JUNG-EUN , LEE GYUN MIN , KIM SUN CHANG , LEE JIE-OH , KIM HAK-SUNG , KOH GOU YOUNG
发明人： JUNG KEEHOON , KIM HOMIN , KIM HAK-ZOO , LEE JUNG-EUN , LEE GYUN MIN , KIM SUN CHANG , LEE JIE-OH , KIM HAK-SUNG , KOH GOU YOUNG
IPC分类号： C12N15/62 , C07K14/705 , C07K16/28 , C07K19/00
CPC分类号： C07K14/705 , C07K2319/32
摘要： The present application discloses a nucleic acid molecule encoding a fusion polypeptide capable of binding myeloid differentiation protein-2 (MD-2) polypeptide, which includes: a nucleotide sequence encoding an MD-2 polypeptide-binding portion of human toll-like receptor 4 (TLR4), a leucine-rich repeats (LRR) module, and a multimerizing component.
摘要翻译：本申请公开了编码能够结合髓样分化蛋白-2（MD-2）多肽的融合多肽的核酸分子，其包括：编码人toll样受体4的MD-2多肽结合部分的核苷酸序列（ TLR4），富含亮氨酸重复序列（LRR）模块和多聚化组分。

3. 发明申请

WO2009090493A2 TLR4 DECOY RECEPTOR PROTEIN 审中-公开
标题翻译： TLR4 DECOY受体蛋白
公开(公告)号：WO2009090493A2
公开(公告)日：2009-07-23
申请号：PCT/IB2008/003936
申请日：2008-12-08
申请人： KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY , JUNG, Keehoon , KIM, HoMin , KIM, Hak-Zoo , LEE, Jung-Eun , LEE, Gyun Min , KIM, Sun Chang , LEE, Jie-Oh , KIM, Hak-Sung , KOH, Gou Young
发明人： JUNG, Keehoon , KIM, HoMin , KIM, Hak-Zoo , LEE, Jung-Eun , LEE, Gyun Min , KIM, Sun Chang , LEE, Jie-Oh , KIM, Hak-Sung , KOH, Gou Young
CPC分类号： C07K14/705 , C07K2319/32
摘要： The present application discloses a nucleic acid molecule encoding a fusion polypeptide capable of binding myeloid differentiation protein-2 (MD-2) polypeptide, which includes: a nucleotide sequence encoding an MD-2 polypeptide-binding portion of human toll-like receptor 4 (TLR4), a leucine-rich repeats (LRR) module, and a multimerizing component.
摘要翻译：本申请公开了编码能够结合骨髓分化蛋白-2（MD-2）多肽的融合多肽的核酸分子，其包括：编码人类toll样受体4的MD-2多肽结合部分的核苷酸序列（ TLR4），富含亮氨酸的重复序列（LRR）模块和多聚体组分。

4. 发明申请

WO2009031834A3 HYBRIDIZATION METHOD BETWEEN LEUCINE RICH REPEAT FAMILY PROTEINS 审中-公开
标题翻译：多种重复家禽蛋白之间的杂交方法
公开(公告)号：WO2009031834A3
公开(公告)日：2009-05-07
申请号：PCT/KR2008005220
申请日：2008-09-04
申请人： KOREA ADVANCED INST SCI & TECH , LEE JIE-OH , KIM HO-MIN , PARK BEOM SEOK , JIN MI SUN , YOO OOK JUN
发明人： LEE JIE-OH , KIM HO-MIN , PARK BEOM SEOK , JIN MI SUN , YOO OOK JUN
IPC分类号： C07K19/00
CPC分类号： C12N15/62 , C07K14/705
摘要： Disclosed is a method for fusing proteins. More specifically, disclosed is a method of fusion between LRR (Leucine Rich Repeat )-famiIy proteins, the method comprising fusing the LRR-family proteins with each other at the following consensus sequence position: LxxLxxLxLxxN, wherein L represents alanine, glycine, phenylalanine, tyrosine, isoleucine, valine or tryptophane, N represents asparagine, glutamine, serine, cysteine or threonine, and X represents any amino acid. According to the disclosed fusion LRR technique, a fusion protein having high crystallinity can be obtained by fusing an LRR-family protein having high crystallinity with another LRR-family protein having low crystallinity. Thus, the fusion LRR technique is useful to determine the structures of proteins having low crystallinity. Furthermore, because the active regions and mechanisms of proteins can be understood from the structural analysis of the proteins, the fusion LRR technique can be effectively to understand the in vivo action of the proteins and develop therapeutic drugs. In addition, according to the fusion LRR technique of the present invention, fusion proteins, which have high crystallinity while maintaining the function of the respective proteins, can be produced in large amounts. Thus, the fusion LRR technique is useful for the development of protein drugs.
摘要翻译：公开了一种融合蛋白质的方法。更具体地，公开了LRR（亮氨酸重复） - 蛋白质融合的方法，所述方法包括在以下共有序列位置将LRR家族蛋白彼此融合：LxxLxxLxLxxN，其中L表示丙氨酸，甘氨酸，苯丙氨酸，酪氨酸，异亮氨酸，缬氨酸或色氨酸，N表示天冬酰胺，谷氨酰胺，丝氨酸，半胱氨酸或苏氨酸，X表示任何氨基酸。根据所公开的融合LRR技术，通过将具有高结晶度的LRR家族蛋白与另外具有低结晶性的LRR家族蛋白融合，可获得具有高结晶度的融合蛋白。因此，融合LRR技术可用于确定具有低结晶度的蛋白质的结构。此外，由于可以从蛋白质的结构分析中了解蛋白质的活性区域和机制，融合LRR技术可以有效地了解蛋白质的体内作用并开发治疗药物。此外，根据本发明的融合LRR技术，可以大量生产具有高结晶度，同时保持各自蛋白质的功能的融合蛋白。因此，融合LRR技术可用于开发蛋白质药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式